CG
NBIX icon

Colony Group’s Neurocrine Biosciences NBIX Stock Holding History

Colony Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$4.57M Sell
40,649
-794
-2% -$83.6K 0.07% 226
2023
Q2 		$3.91M Buy
41,443
+19
+0% +$1.86K 0.06% 257
2023
Q1 		$4.19M Buy
41,424
+33,069
+396% +$3.44M 0.06% 244
2022
Q4 		$998K Buy
8,355
+1,445
+21% +$169K 0.01% 485
2022
Q3 		$734K Sell
6,910
-2
-0% -$203 0.01% 502
2022
Q2 		$674K Buy
6,912
+2
+0% +$185 0.01% 537
2022
Q1 		$648K Sell
6,910
-195
-3% -$16.5K 0.01% 570
2021
Q4 		$605K Sell
7,105
-447
-6% -$41.1K 0.01% 549
2021
Q3 		$724K Hold
7,552
– – 0.01% 488
2021
Q2 		$735K Hold
7,552
– – 0.01% 443
2021
Q1 		$734K Buy
7,552
+377
+5% +$39.5K 0.02% 448
2020
Q4 		$688K Sell
7,175
-1,343
-16% -$130K 0.02% 430
2020
Q3 		$819K Sell
8,518
-617
-7% -$71.4K 0.02% 388
2020
Q2 		$1.11M Sell
9,135
-58
-0.6% -$6.41K 0.03% 331
2020
Q1 		$796K Sell
9,193
-813
-8% -$79.6K 0.03% 377
2019
Q4 		$1.08M Sell
10,006
-5,789
-37% -$606K 0.03% 395
2019
Q3 		$1.42M Sell
15,795
-1,103
-7% -$103K 0.05% 315
2019
Q2 		$1.43M Buy
+16,898
New +$1.39M 0.05% 319

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Colony Group's NBIX Position: Q3 2023 in Review

Colony Group reduced its Neurocrine Biosciences (NBIX) stake by 1.9% in Q3 2023, selling an estimated $83.6K and leaving 40,649 shares worth $4.57M. The position accounts for 0.07% of the portfolio, ranked #226.

Colony Group first reported a position in NBIX in Q2 2019 and has held it in 18 quarters since. 512 funds tracked by Wall St. Rank hold NBIX as of Q3 2023.

  • Colony Group held 40,649 shares of Neurocrine Biosciences worth $4.57M as of Q3 2023.
  • Colony Group sold 794 Neurocrine Biosciences shares in Q3 2023, an estimated $83.6K.
  • Neurocrine Biosciences made up 0.07% of Colony Group's portfolio in Q3 2023, its #226 holding.
  • Colony Group first reported a position in Neurocrine Biosciences in Q2 2019 and has held it in 18 quarters since.
  • 512 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.